51703-20-9Relevant academic research and scientific papers
Synthesis, anti-inflammatory and analgesic activities of arylidene-2-(3-chloroanilino)nicotinic acid hydrazides
Navidpour, Latifeh,Shafaroodi, Hamed,Saeedi-Motahar, Ghazaleh,Shafiee, Abbas
, p. 2793 - 2802 (2014/05/06)
A new series of 2-(3-chloroanilino)nicotinic acid hydrazides 12a-p were synthesized and evaluated for their anti-inflammatory and analgesic activities. Most of the compounds have shown anti-inflammatory activity with a moderate-to-excellent activity range. Among them, 3-chloro 12d and 4-methoxyphenyl derivatives 12i exhibited the most potent anti-inflammatory activity relative to niflumic acid as the reference drug (95, 87, and 81 % reductions in inflammation, respectively). The compounds with the highest anti-inflammatory activity were subjected to analgesic assay and showed moderate-to-excellent analgesic activities. The 2,4-dimethoxyphenyl derivative (12j) exhibited the highest analgesic activity relative to niflumic acid (99.6 and 68 % activity, respectively).
Antiallergy Agents. 1. Substituted 1,8-Naphthyridin-2(1H)-ones as Inhibitors of SRS-A Release
Sherlock, Margaret H.,Kaminski, James J.,Tom, Wing C.,Lee, Joe F.,Wong, Shing-Chun,et al.
, p. 2108 - 2121 (2007/10/02)
A novel class of antiallergy agents, the substituted 1,8-naphthyridin-2(1H)-ones, is described.The present compounds are orally active, potent inhibitors of allergic and nonallergic bronchospasm in animal models.Structure-activity studies of the lead compound in this sereis, 1-phenyl-3-n-butyl-4-hydroxynaphthyridin-2(1H)-one (11), identified three compounds of interest, 1-phenyl-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one (12), 1-(3'-chlorophenyl)-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one (87), and 1-(3'-methoxyphenyl)-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one (89).The mechanism of antiallergy activity may involve inhibition of the release of the sulfidopeptide leukotrienes. 1-Phenyl-3-(2-propenyl)-4-acetoxy-1,8-naphthyridin-2(1H)-one, Sch 33303 (12), was selected for preclinical development as an antiallergy agent.
